info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Primary Osteoarthritis Market Analysis

ID: MRFR//3937-HCR | 120 Pages | Author: Rahul Gotadki| November 2024

The market dynamics of Primary Osteoarthritis is characterized by complex factors that shape the treatment landscape of osteoarthritis. One of the major catalysts behind Primary Osteoarthritis is global aging population. As people age, there are increased cases of osteoarthritis which require more efficient treatments. Growing awareness about arthritis coupled with an expanding elderly population contributes to this market’s continuous growth; it becomes an integral part of musculoskeletal health care system.

Medical research advances and technological innovations play key roles in shaping dynamics within primary osteoarthritis field. Pharmaceutical companies are involved in developing innovative drugs and therapies that reduce symptoms and slow down progression of arthritis disease. This makes the market dynamic because new types of medications like painkillers, NSAIDS, DMOADS (disease-modifying osteoarthritic drugs) find their way into this business area. Regenerative therapy research works alongside personalized interventions for those affected by arthritis are still on-going efforts to differentiate approaches among patients suffering from this condition.

The dynamics of the Primary Osteoarthritis market can be shaped by regulatory factors. Stringent rules exist for the endorsement and commercialization of osteoarthritis drugs and therapies. Pharmaceutical companies’ compliance with regulatory norms is crucial for launching new treatments in the market while ensuring their safety and efficiency. The changing regulation hence affects the development timelines as well as market entry strategies, which in turn influence competitive environment within the osteoarthritis arena.

The competitive landscape that exists among the pharmaceutical industries is a significant part of primary OA’s market dynamics. In this case, companies compete to produce, formulate, and sell more effective, safer, evidence-based products. Partnerships, mergers and acquisitions are frequently used by drug firms to cement their place in the market and expand their product range . Moreover, various treatment options and disease-modifying approaches lead to fierce competition across osteoarthritis industry.

Furthermore, global demographic trends such as population aging and lifestyle changes also impact on Primary Osteoarthritis Market. Aging population is largely responsible for increased prevalence of osteoarthritis indicating need for efficient treatments which can be afforded by many people. Lifestyle aspects like lack of exercise and obesity also contribute to more cases of arthritis thus defining how much it costs to get certain services or goods from superiors. Understanding these demographic shifts will be essential for actors in the Primary Osteoarthritis market who want to create strategies that align with an evolving healthcare landscape.

Global Primary Osteoarthritis Market Overview


Primary Osteoarthritis Market Size was valued at USD 5.63 Billion in 2023. The Global Primary Osteoarthritis industry is projected to grow from USD 6.93 Billion in 2024 to USD 12.56 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 9.42% during the forecast period (2024 - 2032).Arthritis refers to inflammation of the joint, accompanied by joint pain and stiffness. It may be acute or chronic. Obesity, infections, crystal deposition, joint injury, and old age are some of the common causes associated with arthritis. Osteoarthritis and rheumatoid arthritis are two common types of arthritis. Osteoarthritis is a chronic disease, which affects joints, including ligament, cartilage, joint lining, and underlying bones. This disease results in joint pain and stiffness due to the breakdown of cartilage. It is also known as Degenerative Joint Disease (DJD). Primary osteoarthritis and secondary osteoarthritis are the two major forms of osteoarthritis. Primary osteoarthritis results from abnormal stress on weight-bearing joints. This is prevalent mostly in the aging population.


Physical therapy, occupational therapy, chronic pain class, and braces are some of the therapies associated with osteoarthritis. Moreover, osteoarthritis treatment includes surgical procedures such as lubrication injections, cortisone shots, and joint replacement. Rising incidences of surgeries, increasing technological advancements, increasing number of pipeline drugs, and rising awareness about health care are some of the key factors driving the growth of the osteoarthritis market. In addition, rising disposable income in developing countries is also fueling the growth of the osteoarthritis market.


However, stringent regulatory policies and less adoption of osteoarthritis treatment are restraining the growth of the osteoarthritis market. In addition, side effects associated with osteoarthritis medications are also impeding the growth of Primary Osteoarthritis Market.


Intended Audience



  • Primary Osteoarthritis Drug Suppliers

  • Primary Osteoarthritis Drug Manufacturers

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Academic Medical Institutes and Universities


Primary Osteoarthritis Market Segment Insights


The primary osteoarthritis market is segmented on the basis of type, diagnosis, treatment, and end-users.


Primary Osteoarthritis Type Insights


On the basis of the type, the market is segmented into knee osteoarthritis, hand osteoarthritis, neck osteoarthritis, hip osteoarthritis, wrist osteoarthritis, spinal osteoarthritis, shoulder osteoarthritis, and others


Primary Osteoarthritis Diagnosis Insights


On the basis of the diagnosis, the Primary Osteoarthritis Market is segmented into imaging, joint fluid analysis, and others. The imaging segment is further classified into divided X-rays, Magnetic resonance imaging (MRI), and others.


Primary Osteoarthritis Treatment Insights


On the basis of the treatment, the Primary Osteoarthritis Market is segmented into medication, therapies, surgery, and others. The medication segment can be classified into analgesics and non-steroidal anti-inflammatory drugs. The analgesics segment is further classified as acetaminophen, duloxetine, and others. The non-steroidal anti-inflammatory drugs can be further classified into aspirin, ibuprofen, naproxen sodium/ naproxen, and others.


Primary Osteoarthritis End-user Insights


On the basis of the end-user, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.


Primary Osteoarthritis Regional Insights      


The primary osteoarthritis market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.


Currently, North America dominates the osteoarthritis market, followed by Europe. This is due to the rising prevalence of osteoarthritis diseases and growing geriatric population in these regions. In addition, increasing access to health care insurance, especially in the U.S., is also influencing the growth of the Primary Osteoarthritis Market.


The European primary osteoarthritis market is expected to witness rapid growth owing to the high investment in various private and government-funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.


Asia is expected to be the fastest growing market in the next five years. This is due to the rising healthcare infrastructure and increasing government initiatives for better health care facilities in this region. Moreover, a large patient population base is driving the growth of the Primary Osteoarthritis Market in this region.  


The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.


Key Players


The emergence of new and cost-effective medication options for the treatment of osteoarthritis could open up new opportunities for new players in the osteoarthritis market. In addition, emerging markets, such as India and China, could also open new opportunities for new players. Increasing number of strategic alliances between various companies, rising number of product innovations, and increase in the number of clinical trials for pain reliving biologic drugs, such as anti-NGFs, are among the recent market trends in the Primary Osteoarthritis Market.


Some of key the players in the primary osteoarthritis market are



  • Abbott Laboratories (U.S.)

  • Johnson & Johnson Limited (U.S.)

  • Novartis AG (Switerzland)

  • Pfizer, Inc. (U.S.)

  • Eli Lilly and Company (U.S.)

  • Abiogen Pharma (Italy)

  • Ampio pharmaceuticals (U.S.),

  • BioDelivery Sciences International (U.S.)

  • CrystalGenomics (South Korea)

  • Daiichi Sankyo (Japan)

  • Eli Lilly (U.S.)

  • Horizon Pharma (Republic of Ireland)

  • Iroko Pharmaceuticals (U.S.)

  • Merck & Co. Ltd (U.S.)

  • Nuvo Research (U.S.)

  • Regeneus (Australia)

  • Sanofi (France),

  • SantoSolve (U.S.), 

  • Smith & Nephew (UK)

  • Winston Pharmaceuticals (India)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.